Indications and outcomes of extended pancreatectomies have been recently appraised by the International Study Group for Pancreatic Surgery. However, no definitive conclusions have been drawn, particularly in the setting of neoadjuvant treatments. We present here a case of 53-year-old man diagnosed with a bulky adenocarcinoma of the tail of the pancreas and infiltrating the adjacent organs and the thoracic wall. The patient was sent to neoadjuvant chemotherapy and he underwent 12 cycles of FOLFIRINOX. Since a significant radiological response was observed after chemotherapy, the patient was scheduled for extended distal pancreatectomy with en bloc resection of the thoracic wall, in order to achieve a radical resection. The surgery is herein described with all technical details. The patient was discharged after an uneventful early post-operative course and subsequently readmitted for a late grade B post-operative pancreatic fistula, which was ultimately treated successfully. Pathology showed complete response. When performed in centers with ample experience in pancreatic surgery, extended pancreatic resections represent a viable curative option with acceptable surgical outcomes. In this setting, challenging tailored resections should be considered to achieve negative margins, particularly following maximized effective downstaging strategies. 
INTRODUCTION
Microscopic radical resection (R0) is a key predictor of long-term outcome in patients with non-metastatic pancreatic cancer. 1, 2 Borderline resectable and locally advanced tumors can involve adjacent organs or vascular structures.
Thus, they potentially require extended pancreatectomy to achieve a curative radical resection. [3] [4] [5] [6] Over the past decades, heterogeneous definitions of extended pancreatectomy and the indiscriminate use of the terms "extended pancreatectomy" and "multi-visceral resection" have led sections were also included in the definition. 3 Nevertheless, the indications for extended DP are still controversial, particularly in the era of neoadjuvant treatments, with only heterogeneous data available to assess its results.
We present here a case of a locally advanced tumor of the pancreatic tail wherein extended DP with combined multi-visceral resection and thoracic wall resection was performed after a long-course downstaging, along with a brief literature review.
Fig. 1. Axial (A) and coronal (B)
CT scan images performed at diagnosis showed a bulky tumor (arrows) of the pancreatic tail involving the surrounding organs and the abdominal wall. At the CECT for the reevaluation after chemotherapy, the mass was significantly reduced in size, even though borders were barely discernable ( ribs were identified and transected anteriorly and posteriorly to the tumor's infiltration (Fig. 4B) . Pancreatic dissection was then extended to the left and around the tumor, including part of the lateral diaphragm (Fig. 4C) . The resected thoracic wall was eventually removed en bloc with the specimen (Fig. 4D) . Lymph node stations 8a, 8p, 9, 12a, 12p and 12b were selectively sampled. Because of the contaminated field due to the pre-operative collection and the colonic resection, the use of a mesh was unadvisable. Thoracotomy was directly repaired, as well as the diaphragmatic defect (Fig. 4E) . Two running absorbable sutures were used for the end-to-end colonic anastomosis and one closed-system suction drain was left in close proximity to the tumor bed. The overall operative time was 390 minutes and no blood transfusions were However, increased duration of surgery, blood loss, need for transfusions and overall morbidity, along with longer duration of ICU stay and hospital stay were reported. 3 Particularly, overall morbidity was assessed between 42% and 60% after extended pancreatectomy, and between 34% and 58% after standard pancreatectomy.
A subsequent large retrospective monocentric analysis on 611 consecutive cases by Hartwig et al. 6 confirmed a considerable reduction of perioperative outcome for patients undergoing extended pancreatectomy, 8 with surgical morbidity of 42.7% (vs 34.2% among those undergoing standard pancreatectomy) and 30-day mortality of 4.3%.
A similar decrease in post-operative outcome was reported by Schwartz et al., 9 when colectomy was associated to standard pancreatectomy, with 30-day morbidity increasing from 37% to 54% and mortality from 2% to 9%.
Nevertheless, in a recent study, Mitra et al. found no significant differences in peri-operative morbidity (37% vs 29%) and mortality (6% vs 4%) among patients undergoing extended pancreatectomy when compared to standard pancreatectomy, and similar conclusions were reported by Low et al. 10 by analyzing a small retrospective cohort.
Other series only focused on indications and outcomes of extended DP. Roch et al. 11 compared patients undergoing standard DP with those undergoing extended DP in a retrospective analysis. They concluded that similar morbidity and mortality were found between the two groups as well as comparable oncological results. Panzeri et al. 12 reported acceptable morbidity and long-term survival among patients undergoing DP associated with multi-visceral resections. Finally, in a retrospective case-matched analysis by Malinka et al. 5 no differences in terms of complications and survival between standard DP and DP combined with multi-visceral resections were detected. Table 1 3,5,6,9-14 summarizes the studies including series of extended DP and published subsequently to the ISGPS group consensus paper (2014).
Despite the definition provided by the ISPGS group, firm conclusions about indications and outcomes of extended DP are yet to be reached, partially due to the misleading use of the terms 'multi-visceral resection' and extended DP, which included also major vascular resections.
Many of the reported series analyzed both extended pancreaticoduodenectomy and extended DP, without providing any subgroup analysis and often including both pancreatic ductal adenocarcinoma and non-malignant diseases. Moreover, none of them focused on the role of neoadjuvant treatments, neither as possible selection tool for surgery nor as a potential predictor of outcome.
Neoadjuvant strategies such as chemotherapy and radiotherapy have shown to have a key role in terms of disease control and effective downstaging, with excellent rates of subsequent radical resections. [15] [16] [17] [18] It is well accepted, therefore, that patients with locally 
